DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 03 · Volume 40 · May 2007 DOI: 10.1055/s-002-6772

Original Paper

  • 89
    Mauri, M. C.; Colasanti, A.; Rossattini, M.; Volonteri, L. S.; Dragogna, F.; Fiorentini, A.; Valli, A.; Papa, P.:

    Ziprasidone Outcome and Tolerability: A Practical Clinical Trial With Plasma Drug Levels

  • 93
  • 103
  • 107
  • 111
    Stolk, P.; Souverein, P. C.; Leufkens, H. G. M.; Weil, J. G.; Egberts, A. C. G.; Heerdink, E. R.:

    The Association between Exposure to COX-2 Inhibitors and Schizophrenia Deterioration. A Nested Case-Control Study

  • 116
  • 121
    Ulrich, S.; Hiemke, C.; Laux, G.; Müller-Oerlinghausen, B.; Havemann-Reinecke, U.; Riederer, P.; Zernig, G.; Baumann, P.; TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP):

    Value and Actuality of the Prescription Information for Therapeutic Drug Monitoring of Psychopharmaceuticals: A Comparison with the Medico-Scientific Evidence

  • Letter

  • 128
    Bachmann, C.; Grabarkiewicz, J.; Theisen, F. M.; Remschmidt, H.:

    Isotretinoin, Depression and Suicide Ideation in an Adolescent Boy

  • 129
  • 129
  • 132
    Habermeyer, B.; Fuhr, P.:

    Authors' Reply

  • 132
  • Erratum

  • 132